We are live on ! Find out more
SGH

Sivik Global Healthcare Portfolio holdings

AUM $132M
1-Year Est. Return 24.1%
This Fund
S&P 500
This Quarter Est. Return
+13.26%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$232M
AUM Growth
-$69.4M
Cap. Flow
-$146M
Cap. Flow %
-62.7%
Top 10 Hldgs %
36.64%
Holding
63
New
12
Increased
9
Reduced
17
Closed
25

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$8.51M
2
CTLT
CATALENT, INC.
CTLT
+$7.82M
3
BAX icon
Baxter International
BAX
+$7.15M
4
UHS icon
Universal Health Services
UHS
+$6.95M
5
UNH icon
UnitedHealth
UNH
+$6.76M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$35.6M
2
HUM icon
Humana
HUM
+$19.1M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$15.7M
4
SNN icon
Smith & Nephew
SNN
+$11.6M
5
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$9.55M

Sector Composition

Rank Sector Weight
1 Healthcare 98.4%
2 Energy 1.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
26
Merck
MRK
$328B
$4.98M 2.14%
62,880
-26,200
-29% -$2.05M
BMRN icon
27
BioMarin Pharmaceuticals
BMRN
$13.6B
$4.95M 2.13%
65,000
-155,000
-70% -$15.7M
IQV icon
28
IQVIA
IQV
$39.8B
$4.73M 2.03%
+30,000
New +$4.7M
EHC icon
29
Encompass Health
EHC
$12.3B
$4.22M 1.82%
+81,705
New +$4.19M
GH icon
30
Guardant Health
GH
$22.2B
$3.91M 1.68%
+35,000
New +$3.2M
BIO icon
31
Bio-Rad Laboratories Class A
BIO
$9.68B
$3.87M 1.66%
+7,500
New +$3.8M
BDX icon
32
Becton Dickinson
BDX
$50B
$3.72M 1.6%
16,400
-1,806
-10% -$444K
LHCG
33
DELISTED
LHC Group LLC
LHCG
$3.72M 1.6%
17,500
-12,500
-42% -$2.47M
AMED
34
DELISTED
Amedisys
AMED
$3.55M 1.53%
15,000
-10,000
-40% -$2.27M
BIIB icon
35
Biogen
BIIB
$30.9B
$3.4M 1.46%
12,000
-3,000
-20% -$837K
ACH
36
Accendra Health
ACH
$93.1M
$3.14M 1.35%
125,000
-173,700
-58% -$2.53M
NUVA
37
DELISTED
NuVasive, Inc.
NUVA
$2.19M 0.94%
+45,100
New +$2.43M
SEM
38
DELISTED
Select Medical
SEM
$2.19M 0.94%
194,880
-18,560
-9% -$183K
ABBV icon
39
AbbVie
ABBV
$440B
– –
-13,000
Closed -$5.87M
ADPT icon
40
Adaptive Biotechnologies
ADPT
$4.02B
– –
-50,000
Closed -$2.42M
AGIO icon
41
Agios Pharmaceuticals
AGIO
$2.04B
– –
-40,000
Closed -$2.14M
AMRX icon
42
Amneal Pharmaceuticals
AMRX
$6.15B
– –
-600,000
Closed -$2.86M
AZN icon
43
AstraZeneca
AZN
$246B
– –
-30,000
Closed -$9.21M
BLUE
44
DELISTED
bluebird bio
BLUE
– –
-2,702
Closed -$2.14M
BMY icon
45
Bristol-Myers Squibb
BMY
$130B
– –
-60,000
Closed -$3.81M
BNTX icon
46
BioNTech
BNTX
$23.3B
– –
-40,000
Closed -$2.67M
CAH icon
47
Cardinal Health
CAH
$54.5B
– –
-75,000
Closed -$6.46M
CI icon
48
Cigna
CI
$73.3B
– –
-35,000
Closed -$6.31M
CRSP icon
49
CRISPR Therapeutics
CRSP
$5.22B
– –
-30,000
Closed -$2.21M
GILD icon
50
Gilead Sciences
GILD
$168B
– –
-50,000
Closed -$3.85M
1
2
3

Similar funds

AFP
ATX Financial Planning Austin, Texas $132M AUM
PCGDR
Pangea Capital Gestao de Recursos Rio De Janeiro $131M AUM
ACM
Alcosta Capital Management San Ramon, California $131M AUM 34.7% 1-Year Est. Return
9C
9823 Capital Dallas, Texas $132M AUM
STFP
Signal Tree Financial Partners Copley, Ohio $132M AUM 15.43% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $131M AUM 7.53% 1-Year Est. Return
AC
Aldebaran Capital Carmel, Indiana $131M AUM 34.7% 1-Year Est. Return
CIP
Castlefield Investment Partners Manchester $131M AUM

Sivik Global Healthcare's Q3 2020 Portfolio in Review

As of Q3 2020, Sivik Global Healthcare held 63 positions worth $232M, down 23% from $302M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sivik Global Healthcare withdrew a net $146M in Q3 2020, closing 25 positions and reducing 17 holdings. Its most notable exit was Smith & Nephew, an estimated $11.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 95% a quarter earlier, followed by Energy.

Against the trend, Sivik Global Healthcare opened a new position in Eli Lilly worth $8.14M.

  • Sivik Global Healthcare's largest Q3 2020 buy was Eli Lilly: 55,000 shares worth $8.14M.
  • Sivik Global Healthcare added most to Abbott in Q3 2020, an estimated $6.59M increase.
  • Sivik Global Healthcare's biggest Q3 2020 reduction was Thermo Fisher Scientific, cutting an estimated $35.6M.
  • Sivik Global Healthcare fully exited Smith & Nephew in Q3 2020, selling an estimated $11.6M.
  • Sivik Global Healthcare's ten largest holdings make up 37% of its $232M portfolio in Q3 2020.
  • Sivik Global Healthcare opened 12 new positions and closed 25 in Q3 2020.
  • Sivik Global Healthcare's portfolio value fell 23% quarter-over-quarter to $232M.

Based on Sivik Global Healthcare's 13F filing for Q3 2020, filed 13 Nov 2020.